The $195M cash infusion is a significant non-dilutive capital event for a clinical-stage biotech with a $3.7B market cap. Monitor HSR clearance timeline for closing. The proceeds extend Denali's cash runway and de-risk pipeline advancement, watch for upcoming clinical data readouts on DNL126 (Sanfilippo), DNL593 (FTD), and DNL628 (Alzheimer's) as key catalysts.
DNLI drugs
DNLI drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 18 $23.31entry
- T+1 · 5mo ago +3.17%α +3.49% · $24.05
- T+5 · 5mo ago +6.09%α +7.76% · $24.73
- T+20 · 4mo ago −2.49%α −3.02% · $22.73
- T+60 · 2mo ago −8.97%α −10.86% · $21.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Denali Therapeutics (DNLI) announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million in cash. The PRV was awarded following the March 2026 FDA approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome. The $195M cash infusion is a non-dilutive capital event that strengthens Denali's balance sheet and provides funding to advance its broad clinical pipeline of TransportVehicle-enabled programs for lysosomal storage disorders and neurodegenerative diseases, including Sanfilippo syndrome, frontotemporal dementia, Pompe, and Alzheimer's. The transaction is subject to customary HSR closing conditions.
Key Financial Metrics
Key Facts
- Denali entered an asset purchase agreement to sell its Rare Pediatric Disease PRV for $195 million in cash on June 12, 2026
- PRV was awarded following FDA accelerated approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome (MPS II) in March 2026
- Proceeds will fund advancement of clinical pipeline including ETV, OTV, and ATV programs for multiple lysosomal storage disorders and neurodegenerative diseases
- Transaction subject to customary closing conditions including HSR antitrust waiting period expiration
- AVLAYAH is the first FDA-approved biologic designed to cross the blood-brain barrier via transferrin receptor-mediated transport
Financial Impact
$195 million non-dilutive cash infusion from PRV sale
Risk Factors
- PRV sale subject to HSR clearance, closing could be delayed
- Clinical-stage pipeline still unapproved; AVLAYAH is only approved product
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001714899-26-000081 |
| Document: pressreleasedatedjune182026.htm | 0001714899-26-000081 |
| Document: 0001714899-26-000081-index-headers.html | 0001714899-26-000081 |
| Document: 0001714899-26-000081-index.html | 0001714899-26-000081 |
| Document: 0001714899-26-000081.txt | 0001714899-26-000081 |
Track record
17 reports on DNLI
2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +23.19% at T+60 after the May 7, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.75 Now $18.08 −3.55% settles Nov 17
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $20.96 to $19.72 Now $18.08 −13.74% ▼ −5.92% −1.51% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $18.94 to $18.86 Now $18.08 −4.54% ▼ −0.42% +0.06% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $18.66 Now $18.08 −3.11% No price data
- Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $21.40 to $21.09 Now $18.08 −15.51% ▼ −1.45% −2.30% vs SPY
- Sep 4, 202610w ago Insider Cluster Neutral 2/10 Entry $22.08 to $21.57 Now $18.08 −18.12% ▼ −2.31% −1.84% vs SPY
- Aug 6, 202614w ago 8-K Mixed 6/10 Entry $24.83 to $25.00 Now $18.08 −27.18% ▲ +0.68% +0.71% vs SPY
- Jul 27, 202616w ago Press Release Neutral 1/10 Entry $24.05 Now $18.08 −24.82% No price data
- Jun 18, 202621w ago 8-K Bullish 6/10 Viewing Entry $23.31 to $24.05 Now $18.08 −22.44% ▲ +3.17% +3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers